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MaParadoxical embolism is an important clinical entity among patients with venous thromboembolism in the presence of
intracardiac or pulmonary shunts. The clinical presentation is diverse and potentially life-threatening. Although the
serious nature and complications of paradoxical embolism are recognized, the disease entity is still rarely considered and
remains under-reported. This paper provides an overview on the different clinical manifestations of paradoxical embo-
lism, describes the diagnostic tools for the detection of intracardiac and pulmonary shunts, reviews therapeutic options,
and summarizes guideline recommendations for the secondary prevention of paradoxical embolism. (J Am Coll Cardiol
2014;64:403–15) © 2014 by the American College of Cardiology FoundationP aradoxical embolism refers to the clinicalphenomenon of thromboembolism originatingin the venous vasculature and traversing
through an intracardiac or pulmonary shunt into the
systemic circulation (1). The clinical diagnosis requires
a venous source of embolism, an intracardiac defect or
a pulmonary ﬁstula, and evidence of arterial embolism
(2). Depending on the site of embolization, paradoxical
embolismmay result in neurological deﬁcits related to
ischemic stroke (3), chest pain and electrocardio-
graphic changes indicative of myocardial infarction
(MI) (4), acute abdominal pain due to gastrointestinal
ischemia (5), back pain and hematuria as a result of
renal infarction (6), or cold and pulseless extremities
secondary to peripheral arterial occlusion (7) (Fig. 1).
EPIDEMIOLOGY
Cerebrovascular accidents constitute the most fre-
quent relevant clinical manifestations of presumed
paradoxical embolism. The majority of strokes are
ischemic (87%) without identiﬁable cause, despite a
comprehensive stroke work-up in up to 45% of pa-
tients. These strokes are commonly referred to as
nondeﬁned or cryptogenic (8). The prevalence of am the Swiss Cardiovascular Center Bern, Department of Cardiology,
ndecker has received research contracts to his institution from Biotronik,
m Abbott, Biotronik, Boston Scientiﬁc, Biosensors International, Edwards
earch grants to his institution from Abbott, Cordis Corporation, Medtron
noraria and consultant fees from St. Jude Medical. Dr. Stortecky has re
tents of this paper to disclose.
nuscript received August 21, 2013; revised manuscript received March 5,patent foramen ovale (PFO) is increased more than
2-fold among patients with cryptogenic stroke
compared with patients with conventional causes of
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95% CI: 1.0 to 3.7) (9). The true prevalence of para-
doxical embolism is unknown because the clinical
diagnosis of proven or impending paradoxical embo-
lism remains difﬁcult (10), making it a presumptive
diagnosis in most cases. There are likely additional
mechanisms for stroke and transient ischemic attack
(TIA), which remain undescribed and poorly under-
stood. Among these, the pulmonary venous system
remains a “black box” as a potential source of
systemic embolism.
Among patients with transvenous, endocardial
pacing leads, the presence of an intracardiac shunt has
been associatedwith a 3-fold increased risk of systemic
thromboembolism (hazard ratio [HR]: 3.30, 95% CI:
2.19 to 4.96, p < 0.0001), suggesting that paradoxical
embolism is an underlying cause (11). Similarly, in the
presence of a PFO, patients with deep venous throm-
bosis or pulmonary embolism have been found to haveBern University Hospital, Bern, Switzerland. Dr.
and St. Jude Medical; and has received lecture fees
Lifesciences, and Medtronic. Dr. Meier has received
ic, and St. Jude Medical; and has received speaker
ported that he has no relationships relevant to the
2014, accepted April 3, 2014.
ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial ﬁbrillation
ASA = atrial septal aneurysm
ASD = atrial septal defect
CI = conﬁdence interval
HR = hazard ratio
INR = international normalized
ratio
MI = myocardial infarction
MSCT = multislice computed
tomography
OR = odds ratio
PAVM = pulmonary
arteriovenous malformation
PFO = patent foramen ovale
RCT = randomized controlled
trial
TCD = transcranial Doppler
TEE = transesophageal
echocardiography
TIA = transient ischemic attack
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404an increased risk of death and cardiovascular
events in the wake of their acute illness,
compared with control subjects without PFO
(in-hospital mortality, OR: 11.35, 95% CI: 2.89
to 44.52) (12).
It has long been debated whether the
presence of a PFO or another shunt in the
context of cryptogenic stroke represents an
association by chance or a true cause–effect
relationship. Applying criteria developed by
epidemiologists, numerous studies have
established a strong and consistent associa-
tion between the presence of PFO and the risk
of cryptogenic stroke in support of paradoxi-
cal embolism as a responsible mechanism.
Moreover, paradoxical embolism is biologi-
cally plausible, as evidenced by numerous
case reports of thrombi trapped within a PFO
and the typical temporal sequence of events
beginning with venous thrombosis followed
by arterial embolism. In addition, there is
robust evidence documenting a physiological
gradient with an increased risk of paradoxicalembolism being related to shunt size and the addi-
tional presence of an atrial septal aneurysm (ASA) (13).
In aggregate, these data have established PFO as an
independent risk factor of cryptogenic stroke similar
to other known risk factors, such as arterial hyper-
tension, diabetes, or hypercholesterolemia.
PATENT FORAMEN OVALE. By far the most common
intracardiac shunt is a PFO, which is formed by the
left-sided interatrial septum primum and the right-
sided interatrial septum secundum. A patent
connection between the atria may be found in up to
30% of otherwise normal hearts. The prevalence of a
PFO appears to decrease with increasing age, with an
incidence of 34% during the ﬁrst 3 decades, 25%
during the third to seventh decade, and <20% among
octogenarians. The observation of larger PFOs being
present in the elderly (mean size 3.4 mm during the
ﬁrst decade and 5.8 mm during the 10th decade of
life) suggests that there is an ongoing process of
anatomical closure of the PFO during younger age
(14). However, the assessment of PFOs in the elderly
may be less diligent, and small PFOs are more likely
missed; therefore, an alternate theory may be related
to selective mortality by PFO.
Under physiological conditions, a pressure gradient
is maintained between the left and the right atrium,
which results in passive closure of the PFO. In the case
of increased right atrial pressure exceeding left atrial
pressure (as observed at the end of Valsalvamaneuvers
such as coughing, sneezing, squatting, defecation,or micturition), a transient right-to-left shunt may
occur carrying particulate matter such as thrombi
into the systemic circulation. A permanent increase
in right-sided cardiac pressures, as observed after
pulmonary embolism or other causes of pulmonary
arterial hypertension, results in a signiﬁcant and
possibly permanent right-to-left interatrial shunt,
thereby increasing the risk for paradoxical embolism
(12). Patients with a larger PFO size (>4 mm) (15) and
a greater degree of right-to-left shunt as assessed
by crossing microbubbles are at particular risk to
experience paradoxical embolism.
There are some additional anatomical variations
that are frequently associated with PFO:
 A Eustachian valve (Fig. 1) is an embryonic remnant
of the right valve of the sinus venosus that in utero
directs oxygenated venous blood from the inferior
vena cava to the foramen ovale. The Eustachian
valve gradually disappears after delivery in the
majority of individuals; however, residual and
prominent remnants may direct venous blood to
the fossa ovalis and cause signiﬁcant right-to-left
shunt in some individuals. This keeps the fora-
men patent. PFO and residual prominent Eusta-
chian valves thus frequently coexist (70%) and
constitute a common ﬁnding among patients with
presumed paradoxical embolism (16).
 A Chiari network (Fig. 2) is another embryonic
remnant of the right valve of the sinus venosus
and is observed in approximately 2% to 4% of the
general population. Whereas the Eustachian valve
is a tenuous, valve-like ledge, the Chiari network
contains a reticulated complex of threads and
ﬁbers in the right atrium that results from incom-
plete resorption during embryonic heart develop-
ment. Although the Chiari network usually is
an incidental ﬁnding on echocardiography, it is
frequently associated with PFO (83%), a signiﬁcant
right-to-left shunt (55%), or an ASA (24%)—all
facilitating paradoxical embolism (17).
 An ASA describes a ﬂoppy, undulating portion of the
septum primum in the central region where it
overlies the septum secundum. Deﬁned as atrial
septal excursion $10 mm with a base diameter
$15 mm, it is as frequent as 2% in clinical studies
(18). An ASA begets an adult PFO, and themajority of
patients with an ASA indeed have a PFO. Typically,
such a PFO is larger than a PFO without ASA (19), it
may open with every heartbeat, and it is associated
with an increased risk of paradoxical embolism.
ATRIAL SEPTAL DEFECT. According to their loca-
tion, atrial septal defects (ASDs) are categorized as
FIGURE 1 Anatomy of the Interatrial Septum and
Anatomic Variations Associated With PFO
(A) Anatomic characteristics of the interatrial septum (trans-
esophageal echocardiographic long-axis view, right side: cranial,
left side: caudal). (B) Transesophageal echocardiography.
Prominent Eustachian valve, which directs blood from the inferior
vena cava toward the patent foramen ovale (PFO), as evidenced by
the injected bubbles. (C) Transesophageal echocardiography.
Prominent Chiari network in the right atrium (RA). LA¼ left atrium;
RV ¼ right ventricle; SVC ¼ superior vena cava.
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405ostium primum, ostium secundum, sinus venosus, or
coronary sinus defects. ASDs account for one-third of
congenital heart defects in adulthood and are 2 to
3 times more common among females (20). Ostium
secundum defects are the most frequent ASDs (75%)
and are located in the area of the fossa ovalis.
Regardless of the anatomic location, but depending
on the size of the ASD and on its hemodynamic sig-
niﬁcance, patients may experience dyspnea on exer-
tion and fatigue. Patients commonly present withatrial tachyarrhythmias. Patients with ASD have a
relevant risk for paradoxical embolism, which has
been reported with an incidence of up to 14% among
patients referred for ASD closure (21,22).
OTHER SHUNTS. All intracardiac communications,
including ventricular septal defects or cyanotic con-
genital heart defects, have a certain risk for paradox-
ical embolism. Although in most cases, a permanent
left-to-right shunt is observed, a temporary or
chronic increase in right atrial, right ventricular,
or pulmonary pressures over left atrial, ventricular,
or aortic pressures, respectively, may lead to shunt
reversal and paradoxical embolism. By contrast,
patients with pulmonary arteriovenous malforma-
tions (PAVMs) have a permanent right-to-left shunt
permitting the passage of thrombotic or septic emboli
into the systemic circulation.
PAVMs are abnormal vascular communications
directly connecting a pulmonary artery and a pulmo-
nary vein. PAVMs are rare, usually hereditary, and in
most cases, associated with hereditary hemorrhagic
teleangiectasias (23). PAVMs can present with a wide
range of pathologies, including single or multiple,
simple or complex, and unilateral or bilateral pheno-
types of variable size. The physiological consequences
are a permanent right-to-left shuntwith the associated
risk of hypoxemia and paradoxical embolism. Symp-
toms depend on size, number of PAVMs, and shunt
volume, and range from asymptomatic to severely
symptomatic with dyspnea, clubbing, and cyanosis
during exertion or at rest. Observational studies sug-
gest considerable morbidity, which is most frequently
related to neurological complications including
stroke, TIA, and cerebral abscess but can also include
hypoxemia, hemorrhage, and migraine (24).
DIAGNOSIS
The diagnostic evaluation comprises screening for
a thrombotic source, family history, arterial hyper-
tension, diabetes mellitus, hypercholesterolemia, and
tobacco abuse; the search for silent or overt atrial
ﬁbrillation (AF); imaging assessment of the intracra-
nial and extracranial circulation; and transesophageal
echocardiography (TEE) evaluation of the aortic arch
and cardiac chambers. Blood sample analysis serves
to screen for hematologic disorders and coagulation
pathologies (25). In patients with cryptogenic embo-
lism and a coexisting intracardiac communication at
the atrial level, the presumptive diagnosis of para-
doxical embolism should be seriously entertained.
The work-up may be extended to an assessment
of peripheral veins and evaluation for evidence of
pulmonary embolism.
TABLE 1 Accuracy of Diagnostic Modalities for Shunt Detection
Sensitivity Speciﬁcity First Author (Ref. #)
Transesophageal echocardiography Reference method
Transthoracic echocardiography 47% 100% Di Tullio et al. (28)
Transthoracic echocardiography
(harmonic imaging)
68% 93% Clarke et al. (29)
MSCT (64-section) 66% 100% Williamson et al. (31)
MRI 50% 100% Nusser et al. (32)
Transcranial Doppler sonography 68% 100% Di Tullio et al. (28)
Ear oximetry 76% 71% Billinger et al. (34)
MRI ¼ magnetic resonance imaging; MSCT ¼ multislice computed tomography.
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406ECHOCARDIOGRAPHY. Transthoracic echocardiogra-
phy or TEE provides information on cardiac and
valvular function, as well as the presence of intracar-
diac masses (e.g., myxoma) or thrombus. They are the
diagnostic method of choice for the noninvasive
detection of intracardiac shunts and a patent ductus
arteriosus. In addition to information on the localiza-
tion of intracardiac shunts, echocardiography allows
clinicians to assess the size of a defect and provides
information on shunt quantity and direction. Finally,
TEE is the preferred method to exclude large and mo-
bile plaques in the ascending aorta and aortic arch,
which have been associated with an increased risk of
stroke.
The echocardiographic diagnosis of atrial or ven-
tricular septal defects is made by the detection of a
signiﬁcant left-to-right shunt at rest, which can be
detected by color ﬂow Doppler. PFO diagnosis is more
challenging, requiring additional tools. The thorough
evaluation of the fossa ovalis, a shallow depression
in the right atrium composed of the septum primum
and secundum, is a prerequisite for detection of a
PFO (Fig. 1). Most often, left atrial pressure exceeds
right atrial pressure, thereby passively closing the
interatrial communication. Accurate PFO detection
requires peripheral injection of agitated saline or
echocardiographic contrast medium at the end of
a sustained and rigorous Valsalva maneuver. Trans-
femoral or pedal injection of contrast agents can
increase the sensitivity and speciﬁcity of PFO detec-
tion (26). The echocardiographic criteria for PFO
diagnosis include the early detection of contrast
microbubbles in the left atrium within 3 cardiac cycles
after opaciﬁcation of the right atrium (27). PFO size
is estimated using a semiquantitative score. Trans-
esophageal visualization of the interatrial septum for
PFO detection is generally considered to be more
sensitive compared with transthoracic echocardiog-
raphy (28). However, some studies suggest compara-
ble sensitivity of transthoracic techniques with theuse of harmonic imaging to visualize a right-to-left
shunt through a PFO, in case of sufﬁcient imaging
quality (Table 1) (28,29). TEE typically underesti-
mates defect size compared with invasive balloon
measurements of the intracardiac defect.
TRANSCRANIAL DOPPLER SONOGRAPHY. Tran-
scranial Doppler (TCD) is a noninvasive bedside test
with a high sensitivity for the detection of a right-
to-left shunt regardless of its location (Table 1).
After peripheral injection of agitated contrast saline
and adequate Valsalva maneuver, TCD detects
microemboli in the middle cerebral artery and con-
ﬁrms the presence of a right-to-left shunt. Whereas
TEE identiﬁes the defect’s site and size, concomi-
tant intracardiac abnormalities (ASA, persistent
Eustachian valve, or Chiari network), and other car-
diac sources of embolism, TCD detects any kind of
right-to-left shunt including pulmonary shunts (30).
Microemboli also could be (but are not currently)
assessed in an extracranial or limb artery.
COMPUTED TOMOGRAPHY/CARDIAC MAGNETIC
RESONANCE. Multislice computed tomography (MSCT)
provides high spatial resolution images, which allow
a detailed assessment of the vasculature and cardiac
structures during a resting state. Although the
sensitivity and speciﬁcity of MSCT to detect a sig-
niﬁcant intracardiac defect and shunt is considered
high (Table 1) (31), MSCT does not provide infor-
mation on functional aspects of the intracardiac
shunt and precludes Valsalva maneuvers. Moreover,
MSCT is associated with exposure to ionizing radi-
ation, which is of concern among young individuals
in whom it should be avoided as a screening
method.
The relevance of cardiac magnetic resonance im-
aging in the detection of intracardiac shunts remains
controversial. Although small studies show adequate
accuracy to detect intracardiac shunts and a good
correlation with TEE, others question the spatial
resolution during real-time evaluation (32). Again,
Valsalva maneuvers are not possible. However, car-
diac magnetic resonance is very useful for the
noninvasive quantiﬁcation of shunt volume.
EAR OXIMETRY. Ear oximetry is a noninvasive
screening technique that can be applied ubiquitously
and provides high sensitivity (85%; 95% CI: 72% to
93%) and speciﬁcity (100%; 95% CI: 88% to 100%)
comparedwith TEE (33). Ear oximetry for the detection
of intracardiac shunts is based on a simple principle. A
signiﬁcant shunt of desaturated venous blood from the
right atrium into the left circulation causes a drop in
arterial saturation within the ﬁrst few seconds after a
sufﬁcient Valsalva maneuver. This transient fall in
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407systemic oxygen saturation can be noninvasively
monitored in the peripheral circulation and with
ear oximetry. However, a sufﬁcient Valsalvamaneuver
is an important prerequisite for a diagnostically
conclusive result (33,34).
CLINICAL MANIFESTATIONS
Embolic particles can be of different size and diverse
origin and can become clinically relevant in various
ways.
STROKE. Several observational studies have estab-
lished a strong association between stroke and intra-
cardiac shunts, particularly PFO (8,35,36). Young
patients with cryptogenic stroke have been reported
to have a higher prevalence of PFO alone (OR: 5.0; 95%
CI: 2.4 to 10.4), as well as PFO associated with ASA
(OR: 23.3; 95% CI: 5.2 to 103.2) compared with patients
without stroke. Furthermore, in elderly patients
($55 years of age) with cryptogenic stroke, the rate of
PFO was found to be almost 3-fold increased (OR: 2.9;
95% CI: 1.7 to 5.0) and the rate of PFO and ASA was
almost 4-fold increased (OR: 3.9; 95% CI: 1.8 to 8.5)
when compared with patients with known cause of
stroke (8). The association between ischemic stroke
and PFO was conﬁrmed in a meta-analysis on obser-
vational studies with a relative risk of 6.0 (95% CI: 3.7
to 9.7) for patients with PFO and cryptogenic stroke
compared with those with known cause of stroke.
MIGRAINE. There is an association between migraine
and paradoxical embolism. Small emboli originating
from the venous circulation are usually ﬁltered in
the pulmonary circulation, but can enter the systemic
circulation in the presence of a right-to-left shunt and
provoke transient occlusion of the cerebral microcir-
culation (37). In addition, these small thrombi facili-
tate platelet activation and the release of vasoactive
substances and proinﬂammatory markers from the
trigeminal sensory neurons (substance P, calcitonin
gene-related peptide, and neurokinin A), contrib-
uting to migraine attacks (38). The hypothesis of
venous serotonin (usually metabolized in the lungs)
reaching the brain through a PFO and triggering
local vasomotion has also been raised.
Among patients with migraine, the prevalence of
intracardiac right-to-left shunts has been reported to
be as high as 50% (39). Controversy remains whether
PFO closure reduces migraine frequency and severity.
Although observational studies suggest a signiﬁcant
improvement of migraine attacks after PFO closure in
up to 83% of patients (40,41), the prospective MIST
(Migraine Intervention With STARFlex Technology)
randomized controlled trial (RCT) failed to conﬁrmthis hypothesis (42). No signiﬁcant difference was
observed in the primary efﬁcacy endpoint of mig-
raine headache between patients undergoing PFO
closure and sham control subjects 6 months after the
intervention (4.1% vs 4.1%, p ¼ 0.51). However,
exploratory analyses revealed a signiﬁcant reduction
in total migraine headache days in the closure group
(p ¼ 0.027).
MYOCARDIAL INFARCTION. Paradoxical embolism
causing acute MI in the presence of right-to-left shunt
is a potentially fatal and likely under-reported phe-
nomenon (4,43). Acute MI might be the consequence
of paradoxical embolism, which should be enter-
tained in the differential diagnosis (see Fig. 2 for a
case vignette). Histopathological evaluation of the
thrombus aspirate is useful to further substantiate
the origin of thrombotic material and to differentiate
it from atheroembolism and rare other causes, such
as myxomas. Additional clinical manifestations are
described in the Online Appendix.
SECONDARY PREVENTION OF
PARADOXICAL EMBOLISM
Therapeutic approaches include elimination of the
pathway allowing paradoxical embolism to occur
(percutaneous or surgical closure), medical treatment
aiming to prevent recurrence of venous thrombosis,
or its combination. Controversy remains as to the
most effective treatment strategy.
MEDICAL TREATMENT. The most effective medical
therapy for secondary prevention of recurrent events
among patients with paradoxical embolism is un-
known. Acetylsalicylic acid, oral anticoagulation, or
a combination of both can be used. However, the
best regimen to reduce thrombotic events while also
avoiding bleeding complications remains undeter-
mined. In observational studies, the rate of recurrent
cerebrovascular accidents ranged from 3.4% (44) to
14.4% (45) per year using a treatment strategy of
either acetylsalicylic acid or warfarin. Patients with
PFO and ASA are at increased risk for recurrent
ischemic stroke or TIA, and treatment with acetylsa-
licylic acid alone has been shown insufﬁcient for
secondary prevention (44,46).
WARSS (Warfarin Aspirin Recurrent Stroke Study)
(N ¼ 2,206) was a randomized, double-blind, multi-
center trial comparing acetylsalicylic acid (325 mg/
day) with warfarin (target international normalized
ratio [INR]: 1.4 to 2.8) in the prevention of recurrent
stroke (47). Irrespective of PFO presence, there was
no signiﬁcant difference in efﬁcacy between warfarin
and acetylsalicylic acid. Similarly, the multicenter,
FIGURE 2 Clinical Case Vignette
A 34-year-old man was referred for primary percutaneous coronary intervention after
cardiac arrest and resuscitation for ST-segment elevation myocardial infarction compli-
cated by cardiogenic shock (A). Angiography showed severe left ventricular dysfunction
(the arrows indicate anteroapical left ventricular akinesia) (B) due to embolic occlusion of
both the proximal left anterior descending and circumﬂex coronary arteries (arrows) (C).
After thrombus aspiration, balloon dilation under hemodynamic support of a left ven-
tricular assist device (TandemHeart TM, CardiacAssist, Inc., Pittsburgh, Pennsylvania)
and administration of abciximab, coronary ﬂow was re-established (D). Transesophageal
echocardiography revealed a patent foramen ovale (PFO) with spontaneous bidirectional
shunt, suggestive of paradoxical embolism, as the cause of embolic myocardial infarction
(E). The next day, treatment was discontinued due to brain death. Autopsy ﬁndings
included hemorrhagic myocardial infarction (F), a large PFO (G), bilateral subsegmental
pulmonary embolism, and a fresh thrombosis of the left femoral vein. Adapted and
modiﬁed, with permission from Pilgrim et al. (43).
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(N ¼ 630) evaluating warfarin (target INR: 1.4 to 2.8)
and acetylsalicylic acid (325 mg/day) in patients with
PFO and stroke observed no signiﬁcant difference
between both treatment strategies, although the ab-
solute risk for death or stroke was reduced almost
by one-half with warfarin compared with acetylsali-
cylic acid in the subgroup with PFO (48). Of note,
bleeding complications were more common among
patients undergoing oral anticoagulation. In boththe WARSS and PICCS studies, the rate of severe
bleeding complications was similar (WARSS 1.5% vs.
2.2% per 100 patient-years, PICCS 1.8% vs. 1.9% per
100 patient-years), but minor bleeding was more
frequent among patients receiving warfarin (WARSS
13% vs. 21% per 100 patient-years, PICCS 9% vs.
23% per 100 patient-years). The safety and efﬁcacy
of non–vitamin K antagonist oral anticoagulants in
the secondary prevention of paradoxical embolism
has not been studied so far. Given the available evi-
dence investigating non–vitamin K antagonist oral
anticoagulants among patients with AF, deep venous
thrombosis, and pulmonary embolism (49–51), these
agents may be considered a valuable alternative to
warfarin among patients with paradoxical embolism.
PERCUTANEOUS TREATMENT OF INTRACARDIAC
COMMUNICATIONS AND PAVMS. The percutaneous
closure of ASDs was introduced in 1976 (52), followed
by the ﬁrst report of a percutaneous approach to PFO
closure with the Rashkind Clamshell device in 1992
(53). Percutaneous PFO closure has evolved into a
routine, low-risk intervention, which can be easily
performed in an outpatient setting. Complications
are rare but have been reported to include vascular
injury at the puncture site (1.5%), device embolization
(1.1%), cardiac tamponade (0.3%), TIA (0.2%) (54), and
other device-speciﬁc complications, such as early and
late device thrombosis and atrial arrhythmias. Sig-
niﬁcant residual shunt and incomplete closure, as
well as thrombus formation around the device, may be
the cause for recurrent neurological and peripheral
embolic events (55). Overall, PFO closure bears the
lowest risk of percutaneous cardiac interventions,
with an overall risk <1% in an experienced center (56).
The treatment of choice of PAVMs is endovascular
occlusion with intravascular coils or vascular plugs,
whereas surgery (ligation, excision, or pulmonary
segmentectomy) is limited to a few emergency cases
to control bleeding. In the rare clinical scenario of the
coincidence of pulmonary shunts and PFO, treatment
recommendations are lacking, but a percutaneous
approach consisting of PFO and simultaneous pul-
monary shunt closure might be a reasonable option
to reduce the risk of recurrent embolism.
SURGICAL TREATMENT. Surgical treatment of rele-
vant shunts for secondary prevention of cryptogenic
stroke is limited to patients undergoing cardiac
surgery for other indications in view of less-invasive
alternatives. Reports of surgical PFO closure have
indicated closure success with rates of recurrent
ischemic events comparable to those after percuta-
neous PFO closure, ranging between 0% and 14%
(57,58).
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409RANDOMIZED EVIDENCE INVESTIGATING
DIFFERENT TREATMENT STRATEGIES
Observational studies of percutaneous PFO closure
using different devices among patients with presumed
paradoxical embolism have suggested that there is a
substantial beneﬁt in the secondary prevention of
recurrent stroke over medical therapy (59,60). A mor-
tality beneﬁt at 10 years of follow-up was demon-
strated when comparing patients after device closure
to those before or without device closure (59).
Recently, results from 3 randomized, clinical trials
investigating 2 different PFO closure devices (STAR-
Flex, NMT Medical, Boston, Massachusetts, and
Amplatzer PFO Occluder, St. Jude Medical, St. Paul,
Minnesota) compared with medical therapy have been
reported (61–63).
PFO CLOSURE VERSUS MEDICAL THERAPY. CLOSURE I
(Evaluation of the STARFlex Septal Closure System
in Patients with a Stroke and/or Transient Ische-
mic Attack due to Presumed Paradoxical Embolism
through a Patent Foramen Ovale) (61) was the ﬁrst
multicenter, randomized trial comparing the STAR-
Flex closure device with medical therapy using either
warfarin (target INR: 2 to 3) or acetylsalicylic acid
(325 mg/day) among 909 patients with PFO and
cryptogenic stroke enrolled between 2003 and 2008.
The cumulative incidence of the primary endpoint
(stroke or TIA within the ﬁrst 24 months after the
intervention, death from any cause during the ﬁrst
30 days, and death from neurological cause after
30 days up to 24 months of follow-up) was 5.5% in the
closure and 6.8% in the medical therapy groups
(adjusted HR: 0.78, 95% CI: 0.45 to 1.35, p ¼ 0.37).
There were low rates of recurrent stroke (2.9% vs.
3.1%, p ¼ 0.79) and TIA (3.1% vs. 4.1%, p ¼ 0.44) and
no deaths throughout the follow-up period.
PFO closure was effective in 86% of patients after
6 months and 87% of patients after 24 months of
follow-up. Device-associated thrombus was observed
in 1.1% of patients and was considered responsible
for recurrent stroke in 2 patients. PFO closure with
the STARFlex PFO Occluder was associated with an
8-fold increased risk of new-onset AF (5.7% vs. 0.7%,
p < 0.001), which occurred in the ﬁrst week after
the interventions in two-thirds of episodes.
The multicenter, randomized PC (Patent Foramen
Ovale and Cryptogenic Embolism) trial compared the
efﬁcacy and safety of percutaneous PFO closure with
the Amplatzer PFO Occluder with medical therapy
among 414 patients with PFO and a history of cryp-
togenic stroke, TIA, or peripheral embolism (62).
After a follow-up duration of 845 patient-years in the
closure group and 835 patient-years in the medicaltherapy group, the pre-deﬁned combined primary
endpoint of all-cause death, recurrent stroke, TIA, or
peripheral embolism had occurred in 7 patients in the
closure group compared with 11 patients in the med-
ical therapy group (3.4% vs. 5.2%, HR: 0.63; 95% CI:
0.24 to 1.62; p ¼ 0.34). The incidence of recurrent
stroke was low and was observed in 1 patient in the
closure group and 5 patients in the medical therapy
group (0.5% vs. 2.4%, HR: 0.20; 95% CI: 0.02 to 1.72;
p ¼ 0.14). Using the endpoint deﬁnition applied in the
RESPECT trial, a numerical difference in recurrent
stroke was observed between the closure (n ¼ 1) and
the medical therapy groups (n ¼ 7), showing an 86%
relative risk reduction by using the Amplatzer PFO
Occluder compared with medical therapy (HR: 0.14;
95% CI: 0.02 to 1.17; p ¼ 0.07).
Between 2003 and 2011, 980 patients with a med-
ical history of cryptogenic stroke in the RESPECT
(Randomized Evaluation of Recurrent Stroke Com-
paring PFO Closure to Established Current Standard
of Care Treatment) trial were randomly assigned
to PFO closure with the Amplatzer PFO Occluder
(n ¼ 499) and medical therapy (n ¼ 481) (63). Patients
randomized to medical therapy alone were treated
with acetylsalicylic acid (46.5%), warfarin (25.2%),
clopidogrel (14.0%), or dual antiplatelet therapy us-
ing acetylsalicylic acid and clopidogrel (6.2%) or
acetylsalicylic acid and dipyridamole (8.1%). The
maximum follow-up duration was 8.1 years, with
differences in follow-up duration between patients in
the closure and medical therapy group (1,375 patient-
years vs. 1,184 patient-years; p ¼ 0.009), largely
explained by differences in study withdrawal. PFO
closure with the Amplatzer PFO Occluder was asso-
ciated with a high rate of technical (99.1%) and
procedural success (96.1%) and a low rate of peri-
procedural complications (closure vs. medical ther-
apy: bleeding events 1.6% vs. 1.9%; p ¼ 0.81). PFO
closure was effective, showing complete PFO closure
or trivial residual shunt in 94% of patients 6 months
after the intervention.
The endpoint-driven study was stopped when
25 primary endpoints (recurrent stroke or death
within either 30 days after the intervention or
45 days after randomization) were reached. They
occurred in 9 patients in the PFO closure group
compared with 16 patients in the medical therapy
group (HR: 0.49, 95% CI: 0.22 to 1.11, p ¼ 0.08). A
signiﬁcant difference in the primary endpoint was
observed in the per-protocol analysis (HR: 0.37, 95%
CI: 0.14 to 0.96, p ¼ 0.03) and in the as-treated
analysis (HR: 0.27, 95% CI: 0.10 to 0.75, p ¼ 0.007).
Of note, the treatment effect was particularly pro-
nounced among patients with substantial shunt
TABLE 2 Meta-Analyses Comparing PFO Closure With Medical Therapy
First Author
(Ref. #)
Overall Results (ITT) Subgroup Analyses
Conclusions
Recurrent Stroke
(95% CI)
Composite Endpoint
(95% CI) Description
Recurrent Stroke
(95% CI)
Composite Endpoint
(95% CI)
Wolfrum et al.
(65)
RR: 0.66
(0.37–1.19)
NR Per-protocol
analysis
Amplatzer only
RR: 0.66
(0.32–1.38)
RR: 0.44
(0.20–0.94)
NR
NR
Percutaneous PFO closure in
patients with cryptogenic
stroke does not appear to be
superior to medical therapy.
Hernandez and
Moreno
(70)
OR: 0.64
(0.37–1.10)
NR Amplatzer only OR: 0.46
(0.21–0.98)
NR PFO closure with the Amplatzer
Occluder may reduce the
risk of recurrent stroke in
patients with PFO and
cryptogenic stroke.
Dentali et al.
(71)
RR: 0.66
(0.37–1.19)
RR: 0.71
(0.48–1.06)
Atrial septal
aneurysm
Substantial shunt
NR
NR
RR: 0.71
(0.22–2.27)
RR: 0.37
(0.09–1.45)
There is insufﬁcient evidence
to establish the role of
percutaneous PFO closure
in patients with cryptogenic
cerebrovascular events.
Pandit et al.
(72)
HR: 0.62
(0.36–1.07)
NR Amplatzer only HR: 0.44
(0.21–0.94)
NR Percutaneous PFO closure with
the Amplatzer Occluder is
associated with a signiﬁcant
reduction in recurrent
stroke.
Riaz et al.
(73)
NR HR: 0.66
(0.43–1.01)
Per-protocol analysis
Amplatzer only (ITT)
Amplatzer only (PP)
NR
NR
NR
HR: 0.64
(0.41–0.98)
HR: 0.54
(0.29–1.01)
HR: 0.64
(0.44–0.97)
Percutaneous PFO closure
provides a favorable trend
toward improved outcomes
compared with medical
therapy in ITT analyses and
conﬁrms a beneﬁt in PP
analyses.
Khan et al.
(74)
HR: 0.67
(0.44–1.00)
NR Per-protocol analysis
As-treated analysis
Amplatzer only
Amplatzer only (PP)
Amplatzer only (AT)
HR: 0.62
(0.40–0.95)
HR: 0.61
(0.40–0.95)
HR: 0.54
(0.29–1.01)
HR: 0.48
(0.24–0.94)
HR: 0.42
(0.21–0.84)
NR
NR
NR
NR
NR
Percutaneous PFO closure is
beneﬁcial compared with
medical therapy in the
prevention of recurrent
cryptogenic stroke.
Zhang et al.
(75)
RR: 0.66
(0.37–1.19)
NR Amplatzer only RR: 0.48
(0.23–1.02)
NR Percutaneous PFO closure does
not reduce the risk of
recurrent ischemic stroke
compared with medical
therapy.
Hakeem et al.
(76)
RR: 0.66
(0.35–1.24)
RR: 0.71
(0.48–1.06)
Per-protocol
analysis
NR RR: 0.66
(0.43–1.00)
While there is a trend towards
improved outcomes with
PFO closure, there is no
statistical signiﬁcance
compared with medical
therapy.
Nagaraja et al.
(77)
OR: 0.65
(0.36–1.19)
NR Atrial septal
aneurysm
Substantial shunt
RR: 0.7
(0.21–2.33)
RR: 0.35
(0.09–1.41)
NR
NR
Percutaneous PFO closure does
not appear to confer an
advantage over medical
therapy.
Rengifo-Moreno
et al. (67)
HR: 0.62
(0.36–1.07)
HR: 0.67
(0.44–1.00)
Per-protocol analysis
Substantial shunt
Atrial septal
aneurysm
NR
NR
NR
HR: 0.62
(0.38–1.00)
HR: 0.35
(0.12–1.03)
HR: 0.68
(0.32–1.42)
Percutaneous PFO closure may
be beneﬁcial in reducing
the risk of recurrent vascular
events compared with
medical treatment.
Continued on the next page
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410(0.8% vs. 4.3%, p ¼ 0.012) and associated ASA (1.1%
vs. 5.3%, p ¼ 0.016). Device-related thrombus was
observed in none of the patients in the RESPECT
or PC trials during echocardiographic follow-up.
Patients in the closure group had a nonsigniﬁcant
2-fold increased risk for new-onset AF whencompared with patients receiving medical therapy
alone (3.0% vs. 1.5%, p ¼ 0.13). In the RESPECT trial,
the average number of patients that needed to be
treated with the Amplatzer PFO Occluder to prevent
1 stroke amounted to 70 after 2 years and 24 after
5 years of follow-up.
TABLE 2 Continued
First Author
(Ref. #)
Overall Results (ITT) Subgroup Analyses
Conclusions
Recurrent Stroke
(95% CI)
Composite Endpoint
(95% CI) Description
Recurrent Stroke
(95% CI)
Composite Endpoint
(95% CI)
Pineda et al.
(78)
OR: 0.65
(0.36–1.20)
OR: 0.70
(0.47–1.05)
As-treated analysis NR OR: 0.62
(0.41–0.94)
Percutaneous PFO closure
may be associated with a
decreased incidence of
recurrent neurological
events as compared with
medical treatment alone.
Chen et al.
(79)
NR RR: 0.70
(0.47–1.04)
NR NR NR Percutaneous PFO closure is
competitive to medical
treatment and should be
offered to patients as a
choice between a simple
once-in-a-lifetime operation
and lifelong medical therapy
that might increase bleeding
risk.
Ntaios et al.
(80)
OR: 0.64
(0.37–1.10)
NR Amplatzer only OR: 0.46
(0.21–0.98)
NR PFO closure compared with
medical therapy fails
to achieve a signiﬁcant
reduction in stroke. After
pooling only trials using
the Amplatzer PFO occluder,
a signiﬁcant reduction
in stroke over medical
treatment is observed.
Kwong et al.
(81)
OR: 0.65
(0.36–1.20)
NR Amplatzer only OR: 0.47
(0.22–1.02)
NR PFO closure compared with
medical therapy fails
to achieve a signiﬁcant
reduction in stroke.
Kitsios et al.
(69)
HR: 0.55
(0.26–1.18)
HR: 0.67
(0.44–1.00)
Amplatzer only HR: 0.38
(0.14–1.02)
HR: 0.44
(0.17–1.12)
PFO closure compared with
medical therapy fails
to achieve a signiﬁcant
reduction in stroke.
Capodanno et al.
(68)
HR: 0.62
(0.36–1.11)
NR Amplatzer only HR: 0.44
(0.20–0.95)
NR PFO closure compared with
medical therapy fails
to achieve a signiﬁcant
reduction in stroke. After
pooling only trials using
the Amplatzer PFO occluder,
a signiﬁcant reduction in
stroke over medical
treatment is observed.
Spencer et al.
(82)
RR: 0.61
(0.34–1.07)
NR Amplatzer only RR: 0.44
(0.21–0.93)
NR The available randomized
evidence is insufﬁcient to
support PFO closure for
patients with cryptogenic
stroke.
Stortecky et al.*
(83)
NR NR Amplatzer only
StarFlex only
Helex only
RR 0.39 (0.17–0.84)
RR 1.01 (0.44–2.41)
RR 0.71 (0.17–2.78)
NR
NR
NR
The effectiveness of PFO closure
depends on the device used.
PFO closure with the
Amplatzer appears superior
to medical therapy in
preventing strokes in
patients with cryptogenic
embolism
Depicted are analyses from random effects models. *Results from network meta-analysis.
AT ¼ as treated; HR ¼ hazard ratio; ITT ¼ intention to treat; NR ¼ not reported; OR ¼ odds ratio; PFO ¼ patent foramen ovale; PP ¼ per protocol; RR ¼ risk ratio/rate ratio/relative risk.
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411DEVICE TYPE. A randomized trial compared clinical
outcomes and device-speciﬁc differences between
3 different PFO occluders (Amplatzer PFO Occluder,
STARFlex, or HELEX [W.L. Gore & Associates, Newark,
Delaware]; 220 patients per group) among 660 pa-
tients with cryptogenic stroke and PFO (64). Although
technical success was achieved in all patients,signiﬁcant differences in effective PFO closure be-
tween devices were observed (Amplatzer 98.6% vs.
STARFlex 96.8% vs. HELEX 91.8%; p ¼ 0.0012). The
primary endpoint of recurrent cerebral ischemia,
death from neurological cause, or paradoxical embo-
lism within 5 years after the index procedure was
observed in 1.4%, 6.0%, and 4.0% of patients,
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412respectively (p ¼ 0.04). Signiﬁcant differences in
device-associated thrombus formation (0% vs. 5.0%
vs. 0.5%, respectively, p < 0.0001) and new-onset
AF (3.6% vs. 12.3% vs. 2.3%, respectively, p < 0.0001)
were observed during the observational period of
5 years.
META-ANALYSES. All 3 RCTs comparing PFO closure
with medical therapy in the secondary prevention
of cryptogenic stroke or embolism individually
failed to show a statistically signiﬁcant beneﬁt of
PFO closure according to the pre-deﬁned endpoints
(61–63). Several meta-analyses have scrutinized the
available evidence including the RCTs (Table 2). Using
a random effects model, Wolfrum et al. (65) reported
a nonsigniﬁcant 44% relative risk reduction for the
endpoint of stroke (pooled relative risk: 0.66, 95% CI:
0.37 to 1.19; p ¼ 0.171) (65). In a time-to-event anal-
ysis, which considers the time to recurrent stroke
(59,66), a signiﬁcant risk reduction was observed (HR:
0.58, 95% CI: 0.33 to 0.99, p ¼ 0.047). In another
analysis, cerebrovascular events (composite endpoint
of stroke and TIA, according to the intention-to-treat
analysis) were signiﬁcantly reduced (pooled HR: 0.59,95% CI: 0.36 to 0.97; p ¼ 0.04), as was the combined
endpoint of death and vascular events (pooled HR:
0.67, 95% CI: 0.44 to 1.00; p ¼ 0.05) (67).
Capodanno et al. (68) reported no signiﬁcant dif-
ference between percutaneous PFO closure and
medical therapy in the prevention of stroke in a
random effects model, including all 3 RCTs (HR: 0.62,
95% CI: 0.34 to 1.11; p ¼ 0.10). However, analyzing
RCTs according to the implanted device resulted in a
signiﬁcant reduction of stroke (HR: 0.44, 95% CI: 0.20
to 0.95; p ¼ 0.04) when restricting the meta-analysis
to studies using the Amplatzer PFO occluder (62,63),
suggesting a device-speciﬁc effect on clinical out-
comes. Kitsios et al. (69) failed to show a signiﬁcant
reduction for the stroke endpoint using all 3 RCTs
(HR: 0.55, 95% CI: 0.26 to 1.18), whereas a borderline
signiﬁcant effect was observed when analyzing the
composite primary outcomes (HR: 0.67, 95% CI: 0.44
to 1.00) (69). These meta-analyses point to a poten-
tially large treatment effect in favor of percutaneous
PFO closure and suggest that there are device-speciﬁc
differences in outcome potentially related to closure
success and predisposition for thrombus formation
and atrial arrhythmias.
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413CLINICAL DECISION MAKING
In advising individual patients of the treatment
choice between medical treatment alone and percu-
taneous PFO closure, the physician needs to weigh
the overall risk of stroke recurrence, anatomic details
of the structural defect, evidence of venous or pul-
monary thromboembolism, the risks and costs of life-
long antithrombotic therapy in case of medical
treatment, the risks and costs in case of percutaneous
PFO closure, outcomes with various PFO devices, the
potentially large therapeutic beneﬁt of PFO closure
during long-term follow-up, and potential collateral
beneﬁts, such as improvement of headaches or exer-
tional dyspnea. Of note, stroke is different from other
adverse events owing to its impact on sensorimotor
and neurocognitive functions. Available evidence
suggests that PFO closure performed with devices
achieving high closure rates reduces the risk of
recurrent stroke compared with medical treatment
alone and should be considered in patients with
ﬁrst-time cryptogenic stroke, particularly in those
with high-risk criteria, such as presence of an ASA,
large PFO, Eustachian valve, or Chiari network.CONCLUSIONS
Paradoxical embolism is an important clinical entity
among patients with venous thromboembolism and
the presence of cardiac or pulmonary shunts. The
clinical manifestations are serious but diverse and
make the diagnosis challenging at times. The advent
of TEE has greatly facilitated the detection of PFO, the
most important mediator of paradoxical embolism.
Although none of the 3 RCTs individually provided
conclusive evidence in favor of percutaneous PFO
closure over medical treatment alone, synthesis of the
available evidence suggests a substantial treatment
effect in favor of device closure and device-speciﬁc
differences in outcome, which should be conveyed to
patients and considered in the treatment allocation
(Central Illustration).
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APPENDIX For additional information,
including the genetics of intra-atrial defects,
type and source of embolic particles, clinical
manifestations of right-to-left shunt, and
professional guidelines, please see the online
version of this article.
